OncoMatch/Clinical Trials/NCT04405401
Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer
Is NCT04405401 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for lung cancer metastatic.
A registry-based randomized screening phase II trial. A total of 68 patients with metastatic non small cell lung cancer on systemic therapy with oligoprogression to 1-5 extracranial lesions will be randomized using a 1:1 ratio to standard of care (begin next-line systemic therapy, best supportive care, continue current systemic line, based on treating physician decision) vs. receive stereotactic ablative radiotherapy to all oligoprogressive lesions while continuing their current systemic therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Metastatic disease required
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: immune checkpoint inhibitor or tyrosine kinase inhibitor — any line
Oligoprogression while on ICI or TKI (any line)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify